Biohaven Ltd. (BHVN)

Biohaven Ltd.'s stock price has experienced significant fluctuations and a general decline over the past six months, declining by 57.43% from May 5, 2025, to May 1, 2026. Key events include reporting first-quarter 2026 financial results with a narrower net loss, completing enrollment in a Phase 2 obesity study for Taldefgrobep Alfa, releasing fourth-quarter and full-year 2025 financial results with a net loss, highlighting portfolio progress at the 44th Annual J.P. Morgan Healthcare Conference, experiencing an 11.8% stock drop after BHV-7000 failed to meet the primary endpoint in a Phase 2 trial for major depressive disorder, and the FDA rejecting Vyglxia (troriluzole).

As a clinical-stage biopharmaceutical company, Biohaven Ltd. does not have traditional demand seasonality. Its financial performance and demand are driven by research and development progress, clinical trial results, regulatory milestones, and financing activities, which are not seasonal.

Biohaven Ltd. is a global clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing life-changing treatments in immunology, neuroscience, and oncology. The company is advancing a diversified pipeline built around multiple proprietary drug development platforms. Opakalim (BHV-7000) is in Phase 2/3 clinical trials for focal epilepsy and Phase 2 for major depressive disorder. BHV-1300 and BHV-1400 are being developed for Graves' disease and IgA nephropathy (IgAN), respectively, with pivotal studies expected to initiate by mid-2026. Taldefgrobep alfa, an inhibitor of myostatin-activin II receptor signaling pathways, has completed enrollment in a Phase 2 study for obesity, with topline data expected in the second half of 2026, and has potential for neuromuscular conditions like SMA. BHV-1510 (Trop2-directed ADC) is in Phase 1/2 for advanced or metastatic epithelial tumors, and BHV-1530 (FGFR3-directed ADC) is in Phase 1 for urothelial cancer and other tumors. BHV-8000, an orally administered, brain-penetrant TYK2/JAK1 inhibitor, is in a pivotal Phase 2/3 study for early Parkinson's disease. Troriluzole was an advanced product candidate, but its application for spinocerebellar ataxia (SCA) was rejected by the FDA.

Biohaven Ltd. is headquartered in New Haven, Connecticut, United States, and focuses on the worldwide discovery, development, and commercialization of treatments.

Biohaven Ltd. positions itself as focused on developing life-changing treatments and innovative therapies for neurological and immunological diseases. The FDA's rejection of Vyglxia and the failure of BHV-7000 in a Phase 2 trial negatively impacted its reputation. Financial analysts currently hold a "Moderate Buy" consensus rating for BHVN stock, indicating continued confidence in the company's broader pipeline and future prospects.

Biohaven Ltd.'s stock ownership includes institutional, insider, and individual investors. Institutional investors hold approximately 78.70% to 88.78% of the stock, with major holders including Suvretta Capital Management, LLC, Stifel Financial Corp, and BlackRock, Inc. John W. Childs is the largest individual shareholder, owning 10.34% of the company. Insiders collectively own about 10.78% to 15.72% of the stock.